Active Ingredient History
Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders. The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Non-Small-Cell Lung (approved 2004)
Pancreatic Neoplasms (approved 2004)
Adenocarcinoma (Phase 2)
Adenocarcinoma, Bronchiolo-Alveolar (Phase 2)
Adenocarcinoma of Lung (Phase 4)
Adenomatous Polyposis Coli (Phase 2)
Adenomatous Polyps (Phase 2)
Adrenal Gland Neoplasms (Phase 2)
Anemia (Phase 1)
Appendix (Phase 1)
Astrocytoma (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 3)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 1)
Brenner Tumor (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 1/Phase 2)
Carcinoma, Basal Cell (Phase 1/Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Large Cell (Phase 3)
Carcinoma, Mucoepidermoid (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Chemoprevention (Phase 1)
Cholangiocarcinoma (Phase 2)
Cholangitis, Sclerosing (Phase 1)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Drug Therapy (Phase 2)
Endometrial Neoplasms (Phase 2)
Ependymoma (Phase 2)
Epidermal Growth Factor (Phase 2)
ErbB Receptors (Phase 2/Phase 3)
Erlotinib Hydrochloride (Phase 2)
Esophageal Diseases (Phase 2)
Esophageal Neoplasms (Phase 3)
Exanthema (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 1)
Genes, erbB-1 (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Graft vs Host Disease (Phase 2)
Granuloma (Phase 1/Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 3)
Hemorrhagic Fever, Ebola (Phase 1/Phase 2)
Hepatitis C (Phase 1/Phase 2)
Hepatitis C, Chronic (Phase 1/Phase 2)
HIV Infections (Phase 1)
Hodgkin Disease (Phase 1)
Intestinal Neoplasms (Phase 4)
Intestinal Polyposis (Phase 2)
Kidney Neoplasms (Phase 2)
Klatskin Tumor (Phase 2)
Laryngeal Neoplasms (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Liver Cirrhosis (Phase 2)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Meningeal Carcinomatosis (Phase 2)
Meningioma (Phase 1/Phase 2)
Mesothelioma (Phase 2)
Metaplasia (Phase 1)
Mouth Neoplasms (Phase 3)
Multiple Endocrine Neoplasia (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Neoplasms (Phase 2)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasm Recurrence, Local (Phase 2)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Unknown Primary (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 2)
Neuroendocrine Tumors (Phase 2)
Oligodendroglioma (Phase 1/Phase 2)
Oropharyngeal Neoplasms (Phase 1/Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 3)
Pancreas (Phase 2)
Pancreatic Intraductal Neoplasms (Phase 3)
Pancreatic Neoplasms (Phase 4)
Papilloma, Inverted (Phase 1/Phase 2)
Paranasal Sinus Neoplasms (Phase 1/Phase 2)
Pharyngeal Neoplasms (Phase 1/Phase 2)
Pleural Effusion, Malignant (Phase 2)
Polycythemia Vera (Phase 2)
Precancerous Conditions (Phase 1/Phase 2)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Proto-Oncogene Proteins c-met (Phase 2/Phase 3)
Psoriasis (Phase 2)
Rectal Neoplasms (Phase 1/Phase 2)
Respiratory Tract Diseases (Phase 2)
Rhabdomyosarcoma (Phase 2)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Clear Cell (Phase 2)
Sarcoma, Ewing (Phase 2)
Self Efficacy (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Thoracic Neoplasms (Phase 3)
Thymoma (Phase 2)
Thymus Neoplasms (Phase 2)
Thyroid Neoplasms (Phase 1)
Tongue Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Trisomy (Phase 1)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
